B. van de Wiel

机构：The Netherlands Cancer Institute

发表论文 32 篇 · 总被引 1116 次 · h-index 9

代表论文

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (2018 · Nature Medicine · 被引 868)
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019 · Modern Pathology · 被引 32)
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial (2024 · Annals of Oncology · 被引 14)
The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB (2021 · European Journal of Surgical Oncology · 被引 11)
External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. (2018 · Journal of Clinical Oncology · 被引 10)
LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma (2025 · Annals of Oncology · 被引 7)